Dividend Stock: 1973 pharma company; Rs 43 cash reward for shareholders - Record date on Feb 20

Dividend Stock, Pharma Dividend Stock: Alkem Laboratories Ltd recently announced that its board has declared an interim dividend for financial year 2025-2026. Notably, the multinational pharma firm has fixed the record date for the corporate action. The cash reward was announced along with the release of its Q3 quarterly results for FY26.

The record date is when a company identifies shareholders eligible for dividends, stock splits or bonus issues.

The company was incorporated on August 8, 1973, in Patna, Bihar, and later established its headquarters in Mumbai.

"Declared an Interim Dividend of Rs. 43/- (Rupees forty-three only) per equity share on the face value of Rs. 2/- per share for financial year 2025-2026 pursuant to Regulation 43 read with Regulation 30 of SEBI LODR Regulations," the company said in its February 13 dated exchange filing.

"...the record date for the purpose of payment of Interim Dividend for financial year 2025-2026 would be Friday, 20th February, 2026," the filing added.

The company, which had posted a consolidated net profit of Rs 640.79 crore in the corresponding quarter last fiscal, said it has signed a binding term sheet to acquire a majority stake in Swiss medical devices firm Occlutech Holding AG at a "total equity value" of 180.7 million euros.

Consolidated revenue from operations in the third quarter stood at Rs 3,736.82 crore as against Rs 3,374.28 crore in the year-ago period, Alkem Laboratories Ltd said in a regulatory filing.

Total expenses in the third quarter were higher at Rs 3,045.93 crore as compared to Rs 2,736.2 crore in the same period last fiscal, the company said.

In the third quarter, Alkem Laboratories said it had an exceptional item outgo of Rs 52.79 crore on account of the impact of the new labour codes.

(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)